Researchers obtain understanding of pathomechanisms underlying two age-related eye disorders

NewsGuard 100/100 Score

Population aging is a global phenomenon with profound medical implications. Tissue dysfunction associated with aging affects all vital organs, including the eyes. Various ocular structures are affected by aging, such as the macula, the functional center of the retina responsible for precise central vision.

Idiopathic epiretinal membrane (iEMR) and macular hole (MH) are the major vision-threatening vitreoretinal interface diseases that affect millions of aging people globally, making these conditions an important public health issue.

A research team led by Dr. Markku Varjosalo from the Institute of Biotechnology / HiLIFE, University of Helsinki, utilized label-free quantitative mass spectrometry to obtain an in-depth and global understanding of the complex and multi-factorial molecular pathomechanisms underlying the two most typical age-related vitreoretinal interface eye disorders.

The authors show that both iERM and MH are complicated pathological processes involving inflammation, extracellular matrix dysfunction and fibrosis.

Surprisingly, large number of neuronal proteins were abundant in the vitreous proteome of iERM and MH indicating the neurodegenerative background of these age-related pathologies, possibly opening new therapeutic avenues for treating these disorders.

"Currently, there is no known way to pharmacologically impact the development of these two vitreoretinal conditions, making our MS-based investigation a seminal study on shedding light on the role of various proteins in these disease processes.", Dr. Varjosalo states.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema